Eli Lilly obesity pill logs 1,390 U.S. prescriptions in first week

Eli Lilly’s new obesity pill, Foundayo, logged 1,390 U.S. prescriptions in its first week, an early number that gives investors a first look at whether an oral treatment can broaden the market beyond injections. The count is too small to settle the drug’s commercial fate, but it is large enough to matter for a market that has become one of the most lucrative in pharmaceuticals.

Foundayo was approved by the U.S. Food and Drug Administration on April 1 and became available immediately through LillyDirect, with shipping starting April 6. Lilly said broader access through retail pharmacies and telehealth providers followed on April 9, putting the launch on a quick national track. The company set the monthly price at $25 for patients with commercial coverage and $149 for self-pay users, a structure aimed at encouraging uptake in a category where access and out-of-pocket cost often determine whether prescriptions are filled.

The pill’s appeal is not just price. Lilly said adults taking the highest dose lost an average of 27.3 pounds, or 12.4 percent, in the ATTAIN-1 trial, part of a global clinical program that enrolled more than 4,500 people across two studies. Lilly has also emphasized that Foundayo can be taken any time of day without food or water restrictions, a convenience edge that could help it compete with injectable GLP-1 drugs that transformed obesity care but still require injections.

The first-week tally also gives Wall Street a benchmark against Novo Nordisk’s oral Wegovy, which recorded 3,071 U.S. prescriptions in its first four days after launch in January. That comparison is useful, but not exact. Barclays Capital Markets analysts said Novo’s figure reflected retail prescriptions and did not include prescriptions filled through NovoCare Pharmacy. RBC Capital Markets analyst Trung Huynh said Lilly’s first-week comparison may be distorted because the data window captured only two days ending April 10, meaning later days could show a different pace.

The bigger question is whether oral obesity drugs can change who gets treated. If patients who have avoided injections decide a pill is easier to start and stay on, insurers, employers and public programs could face faster adoption and more pressure on drug budgets. The FDA’s approval also came with scrutiny: the agency said it was the first new molecular entity approved under the Commissioner’s National Priority Voucher pilot program and the fastest NME approval since 2002, but it also asked Lilly for additional cardiovascular, liver and lactation data. That leaves Foundayo with a clear commercial opening and a long test ahead.